M
Markku S. Nieminen
Researcher at University of Helsinki
Publications - 493
Citations - 73499
Markku S. Nieminen is an academic researcher from University of Helsinki. The author has contributed to research in topics: Left ventricular hypertrophy & Heart failure. The author has an hindex of 101, co-authored 492 publications receiving 69361 citations. Previous affiliations of Markku S. Nieminen include Helsinki University Central Hospital & Oulu University Hospital.
Papers
More filters
Journal ArticleDOI
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.
Karl Swedberg,John G.F. Cleland,Henry J. Dargie,Helmut Drexler,Ferenc Follath,Michel Komajda,Luigi Tavazzi,Otto A. Smiseth,Antonello Gavazzi,Axel Haverich,Arno W. Hoes,Tiny Jaarsma,Jerzy Korewicki,Samuel Lévy,Cecilia Linde,José-Luis López-Sendón,Markku S. Nieminen,Luc Pierard,Willem J. Remme +18 more
TL;DR: Recent surveys of Guidelines and Expert Consensus Documents published in peer-reviewed journals between 1985 and 1998 have shown that methodological standards were not complied with in the vast majority of cases.
Journal ArticleDOI
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Björn Dahlöf,Richard B. Devereux,Sverre E. Kjeldsen,Stevo Julius,Gareth Beevers,Ulf de Faire,Frej Fyhrquist,Hans Ibsen,Krister Kristiansson,Ole Lederballe-Pedersen,Lars H Lindholm,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Hans Wedel +14 more
TL;DR: Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated, while new-onset diabetes was less frequent with losartan.
Journal ArticleDOI
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Peter S. Sever,Björn Dahlöf,Neil R Poulter,Hans Wedel,Gareth Beevers,Mark J. Caulfield,Rory Collins,Sverre E. Kjeldsen,Arni Kristinsson,Gordon T. McInnes,Jesper Mehlsen,Markku S. Nieminen,Eoin O'Brien,Jan Östergren +13 more
TL;DR: The reductions in major cardiovascular events with atorvastatin are large, given the short follow-up time, and may have implications for future lipid-lowering guidelines.
Journal ArticleDOI
ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).
Kenneth Dickstein,Alain Cohen-Solal,Gerasimos Filippatos,John J.V. McMurray,Piotr Ponikowski,Philip A. Poole-Wilson,Anna Strömberg,Dirk J. van Veldhuisen,Dan Atar,Arno W. Hoes,Andre Keren,Alexandre Mebazaa,Markku S. Nieminen,Silvia G. Priori,Karl Swedberg,Alec Vahanian,John Camm,Raffaele De Caterina,Veronica Dean,Christian Funck-Brentano,Irene Hellemans,Steen Dalby Kristensen,Keith McGregor,Udo Sechtem,Sigmund Silber,Michal Tendera,Petr Widimsky,José Luis Zamorano,Angelo Auricchio,Jeroen J. Bax,Michael Böhm,Ugo Corrà,Paolo Della Bella,Perry M. Elliott,Ferenc Follath,Mihai Gheorghiade,Yonathan Hasin,Anders Hernborg,Tiny Jaarsma,Michel Komajda,Ran Kornowski,Massimo F Piepoli,Bernard Prendergast,Luigi Tavazzi,Jean Luc Vachiery,Freek W.A. Verheugt,Faiez Zannad +46 more
Journal ArticleDOI
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
Björn Dahlöf,Peter S. Sever,Neil R Poulter,Hans Wedel,D Gareth Beevers,Mark J. Caulfield,Rory Collins,Sverre E. Kjeldsen,Arni Kristinsson,Gordon T. McInnes,Jesper Mehlsen,Markku S. Nieminen,Eoin O'Brien,Jan Östergren +13 more
TL;DR: The amlodipine-based regimen prevented more major cardiovascular events and induced less diabetes than the atenolol- based regimen, and these effects might not be entirely explained by better control of blood pressure.